BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Policy

  BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma

  BeiGene, Ltd. announced that the China National Medical Products Administration has accepted a supplemental new drug application for REVLIMID®, in combination with rituximab, for the treatment of patients with relapsed or refractory indolent lymphoma.

  December 22, 2019

   · 

  23 min read
• Drug Development

  Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd

  Progenics Pharmaceuticals, Inc. announced that it will host a conference call to review the top line results from the Phase 3 CONDOR trial of PyL™ in men with biochemical recurrence of prostate cancer on Monday, December 23, 2019, at 8:00 a.m. ET.

  December 22, 2019

   · 

  4 min read